Test Your Knowledge

Quiz: How Have Advances in Lung Cancer Treatment Affected NSCLC Mortality Rates?

09/16/2020

Recent News

Conference Coverage

Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer

01/12/2026

Emily Estrada

In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.

In the BREAKWATER trial,...

01/12/2026

Oncology

News

Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer

01/12/2026

Emily Estrada

Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.

Data from the CAVE-2 GOIM trial...

01/12/2026

Oncology

Conference Coverage

Atezolizumab Plus FOLFIRINOX and Bevacizumab Improves PFS Over Atezolizumab Alone for dMMR/MSI-H Metastatic Colorectal Cancer

01/12/2026

Emily Estrada

Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.

Results from the COMMIT trial...

01/12/2026

Oncology

News

Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes

01/12/2026

Emily Estrada

The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.

The combination of decitabine...

01/12/2026

Oncology

News

Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for R/R Acute Myeloid Leukemia

01/12/2026

Emily Estrada

The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.

The combination of venetoclax...

01/12/2026

Oncology

Conference Coverage

Pharmacogenomic Assay ToxNav Advantage Launches in the US to Assess Fluoropyrimidine Toxicity Risk

01/09/2026

Stephanie Holland

Mira Precision Health has announced the US launch of a new pharmacogenomic assay to identify patients receiving fluoropyrimidine-based chemotherapy, including 5-fluorouracil and capecitabine, who may be at increased risk of severe...

Mira Precision Health has...

01/09/2026

Oncology

Conference Coverage

Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

01/08/2026

Stephanie Holland

Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...

Zolbetuximab plus mFLOFOX and...

01/08/2026

Oncology

Conference Coverage

Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma

01/08/2026

Stephanie Holland

According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.

According to results from the...

01/08/2026

Oncology

Conference Coverage

First-Line Capecitabine Plus Carboplatin Reduces Neurotoxicity Without Compromising Efficacy in Metastatic HER2-Negative Esophagogastric Adenocarcinoma

01/08/2026

Stephanie Holland

According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.

According to results from a...

01/08/2026

Oncology

Conference Coverage

Tabelecleucel Shows Activity and Favorable Safety for Pediatric Patients With R/R EBV-Positive Post-Transplant Lymphoproliferative Disease: ALLELE Trial

12/29/2025

Emily Estrada

Tabelecleucel demonstrated durable responses and favorable safety among pediatric patients with relapsed/refractory Epstein–Barr virus-positive PTLD, according to results presented at the 2025 ASH Annual Meeting & Exposition.

Tabelecleucel demonstrated...

12/29/2025

Oncology